Jazz Pharmaceuticals PLC
(FRA:J7Z)
€
116.8
0.1 (0.09%)
Market Cap: 7.15 Bil
Enterprise Value: 10.62 Bil
PE Ratio: 17.16
PB Ratio: 1.77
GF Score: 83/100 Jazz Pharmaceuticals PLC at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 12:45PM GMT
Release Date Price:
€113
(-0.88%)
David Reed Risinger
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst
Okay. So why don't I kick it off here? Thanks, everyone, for joining. It's very much my pleasure to introduce Jazz Pharmaceuticals. So Bruce Cozadd is the company's Chairman and CEO. He originally cofounded Jazz in 2003 and has served as Chairman and CEO since 2009. So we're fortunate to have you here with us, Bruce.
Questions & Answers
David Reed Risinger
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst
I thought it would be great to just have you start off talking a little bit about the vision that you have for Jazz and how you are acting on that vision and how you plan to execute in coming years.
Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO
Great. And thanks, Dave, for having us here at the conference. I will say before I start, I'll make forward-looking statements. Please see our SEC filings for risk
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot